Overview

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

Status:
Recruiting

Trial end date:
2022-07-30

Target enrollment:

Participant gender:

Summary

A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome

Phase:

Phase 2

Details

Lead Sponsor:

Woolsey Pharmaceuticals

Treatments:

Fasudil